Quantcast
Home > Quotes > AKBA

Akebia Therapeutics, Inc. Common Stock (AKBA) Quote & Summary Data

AKBA 
$8.39
*  
0.31
3.56%
Get AKBA Alerts
*Delayed - data as of Mar. 22, 2019  -  Find a broker to begin trading AKBA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    AKBA After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 8.20 / $ 8.76
Today's High / Low
$ 8.97 / $ 8.38
Share Volume
1,224,143
50 Day Avg. Daily Volume
1,091,275
Previous Close
$ 8.70
52 Week High / Low
$ 12.09 / $ 5.20
Market Cap
980,686,276
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
1,224,143
50 Day Avg. Daily Volume:
1,091,275

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.29

Trading Range

The current last sale of $8.39 is 61.35% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 8.97 $ 12.09
 Low: $ 8.38 $ 5.20

ETFs with AKBA as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
3.47% Invesco Dynamic Biotech & Genome ETF (PBE) +6.50 (13.19%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on developing and commercializing novel therapeutics for patients based on hypoxia-inducible factor, or HIF, biology, and building our pipeline while leveraging our development and commercial expertise in renal disease. HIF is the primary regulator of the production of red blood cells, or RBCs, in the body, as well as other important metabolic functions. Pharmacologic modulation of the HIF pathway may have broad therapeutic applications. Our lead product candidate, vadadustat, is an oral therapy in Phase 3 development and has the potential to set a new standard of care in the treatment of anemia due to chronic kidney disease, or CKD. Our management team has extensive experience in developing and commercializing drugs for the treatment of renal and metabolic disorders, as well as a deep understanding of HIF biology.  ... More ...  



Risk Grade

Where does AKBA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 8.65
Open Date:
Mar. 22, 2019
Close Price:
$ 8.39
Close Date:
Mar. 22, 2019


Consensus Recommendation

Analyst Info